Previous studies of LPCAT enzymes in cancer have shown that they are independent predictors of early tumour recurrence and prognostic markers for several cancers.29–31 Particularly, the expression level of LPCAT2 was positively correlated with aggressive prostate cancer;32 however, the impact of increased LPCAT2 expression on clinical progression remains unknown in HNSCC patients. This evidence concerns the gene LPCAT2 and prostate cancer.